More about High-Yield Cash Accounts with M1
Brokerage Accounts
Retirement Accounts
Other Accounts
Quotes are delayed by 15 minutes.
1D
1W
1M
3M
6M
YTD
1Y
2Y
5Y
ALL
Market cap
$39.64B
EPS
-1.13
P/E ratio
--
Price to sales
21.34
Dividend yield
--
Beta
1.547694
Previous close
$289.92
Today's open
$286.69
Day's range
$271.85 - $288.41
52 week range
$181 - $437.41
show more
CEO
Steven Chapman
Employees
6140
Headquarters
Austin, TX
Exchange
Nasdaq Global Select
Shares outstanding
145004521
Issue type
Common Stock
Healthcare
Medical Diagnostics & Screening
Natera vs. Tempus AI: Which Blood Test Pioneer Has the Better Stock Buy for 2027?
Natera dominates the molecular diagnostics market with high revenue growth and positive free cash flow. Tempus AI leverages a massive multimodal data library and artificial intelligence to drive precision medicine.
The Motley Fool • Nov 19, 2026

Allspring Mid Cap Growth Fund Q3 2026 Contributors And Detractors
Allspring Mid Cap Growth Fund outperformed the Russell Midcap Growth Index during the third quarter. Top contributors include Twilio, Natera, Astera Labs, Cloudflare and Bloom Energy Corp. Top detractors include Carpenter Technology, RB Global, Viking Holdings, UL Solutions and Curtiss-Wright Corp.
Seeking Alpha • Nov 19, 2026

Alger Capital Appreciation Fund Q3 2026 Portfolio Activity
Microsoft Corporation, NVIDIA Corporation, and Natera, Inc. were among the top contributors to performance. We believe Nvidia is a direct beneficiary of the AI infrastructure buildout given its strong competitive position, robust product roadmap, and expanding market opportunity. Western Digital Corporation, Nebius Group, and Astera Labs, Inc. were among the top detractors from performance.
Seeking Alpha • Nov 18, 2026

HLTH 2026 Names Natera Best-in-Class Winner in Cancer, Screening & Early Detection
AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (Nasdaq: NTRA), a global leader in cell-free DNA and precision medicine, today announced that it has been named the Best in Class winner in the Cancer, Screening & Early Detection category at the Digital Health Hub Foundation Digital Health & AI Awards. The recognition highlights the impact of Natera's Signatera™ molecular residual disease (MRD) test on cancer care.The winners were announced live at the 2026 HLTH Conference in Las Vegas. This.
Business Wire • Nov 17, 2026

Natera CFO Maps Multiple Paths to $6 Billion Revenue Target by 2029
Natera NASDAQ: NTRA Chief Financial Officer Mike Brophy said the company has multiple paths to its $6 billion revenue target for 2029, citing growth in its Signatera cancer testing business and opportunities to improve reimbursement.
MarketBeat • Nov 15, 2026

Natera CFO Defends CEO Switch, Calls $6 Billion Revenue Target a “Way Station”
Natera NASDAQ: NTRA CFO Mike Brophy said the company's newly announced $6 billion revenue target for 2029 is achievable with strong execution, as he outlined expectations for its Signatera cancer test and defended the immediate transition to a new CEO.
MarketBeat • Nov 14, 2026

Natera, Inc. (NTRA) Presents at 8th Annual Wolfe Research Healthcare Conference Transcript
Natera, Inc. ( NTRA ) 8th Annual Wolfe Research Healthcare Conference November 10, 2026 12:00 PM EST Company Participants Mike Brophy - Chief Financial Officer Conference Call Participants Paige Chamberlain - Wolfe Research, LLC Presentation Paige Chamberlain Wolfe Research, LLC Hi, everyone. Thanks for being here.
Seeking Alpha • Nov 11, 2026

Natera, Inc. (NTRA) Presents at 2026 UBS Global Healthcare Conference Transcript
Natera, Inc. ( NTRA ) 2026 UBS Global Healthcare Conference November 9, 2026 8:00 AM EST Company Participants Mike Brophy - Chief Financial Officer Conference Call Participants Douglas Schenkel - UBS Investment Bank, Research Division Presentation Douglas Schenkel UBS Investment Bank, Research Division All right. Good morning, everybody.
Seeking Alpha • Nov 11, 2026

Natera Announces Clinical Collaboration with Incyte on Interventional Phase II Study in Colorectal Cancer
AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (Nasdaq:NTRA), a global leader in cell-free DNA and precision medicine, today announced that it has entered into a clinical collaboration agreement with Incyte (Nasdaq:INCY) for a new phase II study in colorectal cancer (CRC). The trial will evaluate INCA33890, Incyte's investigational bispecific immunotherapy, in patients with stage 2/3 CRC who have completed surgery and adjuvant chemotherapy (ACT), incorporating Signatera as both a primary and seco.
Business Wire • Nov 10, 2026

NTRA Q3 Loss Wider Than Expected, Revenues Beat, '26 Sales View Up
Natera???s Q3 revenues jump 34.1%, beating estimates, while a wider-than-expected loss and surging oncology test volumes shape its raised 2026 sales outlook.
Zacks Investment Research • Nov 9, 2026

¹ Disclosures

Open an M1 investment account to buy and sell Natera Inc. commission-free¹. Build wealth for the long term using automated trading and transfers.